

11 DECEMBER 2025

ASX RELEASE

ADDITIONAL CONFIRMED RESPONSE REPORTED AS PART OF AMPLIA INVESTOR PRESENTATION

HIGHLIGHTS

- *An additional confirmed partial response has been recorded in the ongoing ACCENT trial*
- *This brings the confirmed Objective Response Rate to 35%*
- *Updated data to be presented at the Life Sciences Virtual Investor Forum*

Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing **ACCENT** trial in metastatic pancreatic cancer. The trial investigates the combination of the Company’s best-in-class FAK inhibitor narmafotinib in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®).

The additional PR brings the confirmed objective response rate (ORR) to 35% (19/55) which compares favourably to the ORR of 23% recorded for gemcitabine and nab-paclitaxel alone in the benchmark MPACT trial upon which ACCENT is based.

A presentation outlining the data from the ACCENT trial will be presented by Amplia CEO Dr Chris Burns at the Life Sciences Virtual Investor Forum on Thursday December 11 at 3pm US ET (Friday December 12 7am AEDT) and is attached to this announcement.

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com
Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:

Robert Giordano
rjgiordano@ggrouplifesciences.com

+1 917 327 3938

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

U.S. Media:

media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the [ACCENT](#) trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.6 months has also been reported. A second trial – [AMPLICITY](#) – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.



Life Sciences Virtual Investor Forum

11 December 2025

Chris Burns PhD

ampliatx.com | [@ampliatx](https://twitter.com/ampliatx)
ASX: ATX | OTCQB: INNMF



DISCLAIMER

This presentation (**Presentation**) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the **Company** or **Amplia**) which is current as at 30 September 2025. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia's most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation.

Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance.

Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia's actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company's good faith assumptions as to the financial,

market, regulatory and other relevant environments that will exist and affect Amplia's business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia nor its representatives have independently verified any such market or industry data.

Financial Information: This Presentation contains historical financial information based on the Company's results for the 12 month period ending 30 September 2025 and management accounts to 30 September 2025. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding.

Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement.

EXECUTIVE SUMMARY

Developing a pipeline of small molecule inhibitors of FAK



Lead drug **narmafotinib** is best-in-class FAK inhibitor in development



Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer



New trial of narmafotinib in pancreatic cancer now underway



FAST-track and **Orphan Drug Designation** granted from US FDA

BOARD + MANAGEMENT

World-class experts

BOARD



Warwick Tong
MB ChB MPP GAICD
Chair



Robert Peach
PhD
Director



Jane Bell
LLB LLM (Lond) FAICD
Director



Chris Burns*
PhD GAICD
CEO and MD



SENIOR MANAGEMENT



Rhiannon Jones
PhD GAICD
COO



Jason Lickliter
MBBS FRACP
CMO




Tim Luscombe
BCom CA GIA(Cert)
CFO

METASTATIC PANCREATIC CANCER

Limited treatment options; poor patient outcomes

5Y Survival




Highly aggressive with multiple genetic drivers

>50% pancreatic cancer patients diagnosed with **advanced** (metastatic, stage 4) disease at the time of diagnosis

Limited Treatment Options

Treatment	Median Progression Free Survival	Median Overall Survival	Tolerability
Gemcitabine + nab-paclitaxel (MPACT study)	5.5 months	8.5 months	😐
FOLFIRINOX (Prodige study)	6.4 months	11.1 months	😞

Most patients receive gemcitabine + nab-paclitaxel or FOLFIRINOX or variations of these[†]



FAK INHIBITION IN CANCER

FAK enzyme overactive in pancreatic cancer

FAK levels are elevated in pancreatic cancer

- Correlate with worse patient outcome

FAK inhibition blocks processes that support:

- Tumour growth
- Metastasis
- Treatment resistance

FAK over-activity in both cancer cells and surrounding cells

- Cause fibrosis *and* immune suppression


Benefits of FAK Inhibition

Anti-proliferative
Reduces cells' ability to proliferate and migrate

Synergy with chemotherapies
Enhances activity of drugs and other therapies

Anti-fibrotic
Reduces scar-tissue in TME, improving permeability to drugs

Immunomodulatory
Improves immune cell reactivity to tumour cells



Tumour (blue - cancer cells; green- fibroblasts; purple, grey and yellow - suppressive immune cells)

NARMAFOTINIB

A Potent and Selective FAK Inhibitor


Drug-like small molecule

- Potent activity in laboratory models of human pancreatic cancer
- Once a day oral dosing by capsule
- Storage at room temperature

Safe to combine with other medicines

- No evidence of drug-drug interactions

Evidence of FAK target engagement preclinically and in the clinic



ACCENT TRIAL IN PANCREATIC CANCER

Phase 1b/2a study in Australia and Korea

OBJECTIVE

- To determine safety and efficacy of narmafotinib in combination with gemcitabine and nab-paclitaxel
- Patients with newly diagnosed metastatic disease

PRIMARY ENDPOINTS

- Safety, Tolerability
- ORR (RECIST 1.1)*

ADDITIONAL ENDPOINTS

- Duration on Trial (DoT)
- Progression free survival (PFS)
- Overall Survival (OS)
- Disease Control Rate

Demographics	
Patient # (total study)	55
Geographic area (%)	Australia (44%) / Korea (56%)
Female (%)	49%
Age median (min-max)	64 (37 - 87)
ECOG PS 0	17 (31%)
ECOG PS 1	38 (69%)
Ethnic background	
• Caucasian	21 (38%)
• Asian	33 (60%)
• Australian Aborigine / Torres Strait Islander	1 (2%)

* ORR - Objective Response Rate; RECIST - Response Evaluation Criteria in Solid Tumours, *Eur J Canc.* 2009, 45, 228-247.

ACCENT TRIAL TOPLINE DATA


Promising evidence of efficacy, durability and tolerability

Median Progression Free Survival (mPFS) data

- Currently determined at 7.6 months - substantially better than chemotherapy alone (5.5 months)
- Improvement over FOLFIRINOX chemotherapy (6.4 months)

	ACCENT Trial (Narmafotinib/Gemcitabine/Abraxane)	MPACT Trial (Gemcitabine/Abraxane)	PRODIGE Trial (FOLFIRINOX)
mPFS	7.6 months	5.5 months	6.4 months

All ACCENT patients @ 400 mg (n = 64)



ACCENT TRIAL INTERIM DATA

Promising evidence of efficacy, durability and tolerability

Excellent response rate observed

- **1 confirmed Complete Response (CR)**
- **18 confirmed Partial Responses (PR)**
 - Incl. 1 patient determined to be a **pathological Complete Response**
- **Confirmed** objective response rate (ORR) of 35%
 - Unconfirmed objective response rate 42%
- Disease control rate (DCR) of 76%

	ACCENT Trial (Narmafotinib/Gemcitabine/ nab-paclitaxel)	MPACT Trial (Gemcitabine/ nab-paclitaxel)
CR	2%	0.2%
PR	33%	23%
SD	44%	27%
PD	13%	20%
NE	11%	30%
ORR	33%	23%
DCR	76%	50%
DoT	219 days	117 days


ACCENT TRIAL TOPLINE DATA

Promising evidence of efficacy, durability and tolerability

Excellent tolerability observed to date


- Narmafotinib treatment results in negligible extra patient burden

Adverse Events (Grade 3 or above)



THE AMPLIA ADVANTAGE

Three critical features



FUTURE OPPORTUNITIES

FAK inhibition will enhance multiple therapeutic strategies

Narmafotinib
(FAK inhibition)



CHEMOTHERAPY

Clinical and preclinical data incl.
ACCENT study

KRAS INHIBITORS

Preclinical data, incl.  **NEXT&BIO**
collaboration

IMMUNOTHERAPIES

Preclinical data

RADIOTHERAPY

Published data

**ANTIBODY DRUG
CONJUGATES**

Published data

AMPLICITY TRIAL in mPDAC

Phase 1b/2a study in the US and Australia

OBJECTIVE

- To determine safety and efficacy of narmafotinib when added to FOLFIRINOX in newly diagnosed metastatic patients


TRIAL DESIGN

- Dose escalation phase (up to 27 patients)
- Dose expansion phase (40 patients)

TRIAL UNDERWAY

- Under IND
- 2 sites in Australia
- 5 Sites in US
 - Opening over coming weeks


Moving from intermittent to daily dosing



FUTURE MILESTONES

Key deliverables

ACCENT (NARMAFOTINIB + GEMCITABINE + ABRAXANE)



AMPLICITY (NARMAFOTINIB + FOLFIRINOX)



THANK YOU

Chris Burns PhD
chris@ampliatx.com

Amplia Therapeutics Limited
ASX: ATX | OTCQB: INNMF
info@ampliatx.com

ampliatx.com

